v3.26.3
Segment Information - Schedule of Reconciliation to Consolidated Operating Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Total research and development expenses $ 53,843 $ 45,874 $ 152,576 $ 129,965
General and administrative expenses 25,362 18,087 72,246 54,433
Total operating expenses 79,205 63,961 224,822 184,398
INHBE Program [Member]        
Segment Reporting [Line Items]        
Total research and development expenses 6,374 4,574 18,080 10,628
AATD Program [Member]        
Segment Reporting [Line Items]        
Total research and development expenses 3,057 967 7,796 4,259
DMD Program [Member]        
Segment Reporting [Line Items]        
Total research and development expenses 3,633 4,973 11,724 10,692
HD Program [Member]        
Segment Reporting [Line Items]        
Total research and development expenses 250 487 470 2,443
Other Research and Development Expenses, Including PNPLA3, Additional Preclinical Programs, PRISM [Member]        
Segment Reporting [Line Items]        
Total research and development expenses $ 40,529 $ 34,873 $ 114,506 $ 101,943